CareFusion has agreed to pay $41 million to settle a 2-year federal probe into the sales and marketing of its ChloraPrep line of antiseptic wipes. The settlement will allow the San Diego, Calif.-based medical device company to avoid prosecution and will bring the investigation to an end. The probe was started in 2011 and involved questions on how CareFusion marketed the ChloraPrep skin preparation products to physicians and other healthcare workers.
The investigation began when CareFusion received a U.S. Justice Department subpoena in April 2011, seeking information on the company’s “relationships with healthcare professionals,” according to regulatory filings. Last month, the FDA classified the recall of CareFusion’s Alaris PC software as Class I, the most serious recall level, denoting the risk of serious injury or death. This is the latest in a series of regulatory warnings and recalls for some of the Alaris infusion pump line, designed to electronically control drug and fluid delivery to patients.
Source: Associated Press
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.